Richeldi L, Crestani B, Azuma A, et al. - Researchers present findings from the INPULSIS and INPULSIS-ON trials of nintedanib in patients with IPF, focusing on the influence of FVC decline on subsequent FVC reduction and death. They found that subsequent FVC reduction was not predicted by a decline in FVC but a link was discovered between decline in FVC and mortality in patients with IPF. Higher mortality between weeks 24 and 52 of INPULSIS was reported in correlation with FVC decline ≥ 10% predicted vs < 10% predicted between baseline and week 24 (13.2% vs 3.8%). Reduction in FVC ≥ 10% predicted in the first year of INPULSIS-ON was detected among nintedanib-treated patients in INPULSIS who showed a decline in FVC ≥ 10% vs < 10% predicted at week 52, 34.0% vs 21.4%, respectively. These groups exhibited 21.3% vs 5.7% of mortality in the first year of INPULSIS-ON, respectively.